Clinical Trial Update: Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial assessing APR-246 plus azacitidine in TP53-mutant myeloid neoplasms completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• APR-246 (eprenetapopt)
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-25